$VSTA Stem Cell Bio Mega dd
VSTA Business Description
VistaGen Therapeutics Inc. is biotechnology company harnessing the revolutionary power of human pluripotent stem cell technology for drug rescue and cell therapy.
VistaGen's drug rescue activities involve the combination of its human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity, despite promising efficacy data. VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube(TM), is based on directed differentiation (development) of human pluripotent stem cells into multiple types of mature cells. With heart cells produced from stem cells, VistaGen has developed CardioSafe 3D(TM), a three-dimensional biological assay (screening) system the company believes is capable of predicting the human cardiac effects, both toxic and non-toxic, of new drug candidates, long before they are tested in humans. VistaGen's immediate goal is to leverage CardioSafe 3D(TM) to generate and monetize a pipeline of small molecule drug candidates through drug rescue collaborations. VistaGen intends to expand its drug rescue capabilities by introducing LiverSafe 3D(TM), a human liver cell-based toxicity and metabolism bioassay system. In collaboration with Dr. Gordon Keller, recently named a "Top 25 Transformational Canadian" for his pioneering stem cell research and technology, VistaGen is also advancing pilot preclinical development of large market cell therapy programs, including cartilage, heart and liver repair
VSTA Pipeline and Technologies
Human Clinical Trials in a Test Tube™
$VSTA CardioSafe 3D™ is a novel bioassay system that uses mature human heart cells derived from pluripotent stem cells to screen for heart toxicity in connection with our drug rescue activities. We believe CardioSafe 3D™ is stable, reproducible and capable of generating data to allow more accurate prediction of the in vivo cardiac effects, both toxic and nontoxic, of promising new drug candidates long before they are tested in humans.
$VSTA LiverSafe 3D™
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, we are developing engineered cell lines and enhancing protocols to control the differentiation of pluripotent stem cells into normal, mature, human liver cells for use in a novel liver cell-based bioassay system for predicting liver toxicity and metabolism issues in connection with our drug rescue activities. We refer to this novel human liver cell-based bioassay system as LiverSafe 3D™. We plan to complete development of LiverSafe 3D in early-2013.
$VSTA AV-101, also known as “L-4-chlorokynurenine” and “4-Cl-KYN”, is a novel prodrug candidate that we are developing for the treatment of neuropathic pain. We are also considering AV-101 Phase 2 development opportunities relating to epilepsy, Parkinson’s disease and depression.
AV-101 is a novel, orally available prodrug that is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which is an antagonist of the N-methyl-D-aspartate (NMDA) receptors. 7-Cl-KYNA is a synthetic analogue of kynurenic acid, a naturally occurring CNS regulatory compound, and is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
In pre-clinical studies, AV-101 has demonstrated very good levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier and preferential conversion into 7-CKYNA at the site of seizures and potential neural damage in the brain and spinal cord.
AV-101 is completing Phase 1 development in the U.S. under an active Investigational New Drug (IND) application on file at the U.S. FDA that defines the initial clinical development for neuropathic pain.
We believe the safety studies completed in our AV-101 Phase 1 clinical program may also enable Phase 2 development of AV-101 for epilepsy, Parkinson’s disease and depression.
Technology: http://www.vistagen.com/technology/default.aspx
Our Human Clinical Trials in a Test Tube™ platform is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by our co-founders, renowned Canadian stem cell scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our President and Chief Scientific Officer.
Relevant Publications Relating to Licensed Technologies: http://www.vistagen.com/?page_id=322
VSTA Product Line: http://www.vistagen.com/products/Clinical-Trials-in-a-Test-Tube/default.aspx
VSTA Business Model: http://www.vistagen.com/business-model/default.aspx
VSTA VistaGen Fact Sheet: http://www.vistagen.com/Investors_Overview/default.aspx
VSTA daily chart:
VSTA Key Company Management
Shawn K. Singh CEO
H. Ralph Snodgrass President, CSO
Jerrold D. Dotson CFO
A. Franklin Rice VP, Corp. Dev.
Shawn Singh, J.D.
Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies,serving in numerous senior management roles. He served as Managing Principal of Cato BioVentures, a biopharmaceutical venture capital firm, as Chief Business Officer of Cato Research Ltd., a global contract research and development organization (CRO), as President of Echo Therapeutics (Nasdaq: ECTE), a medical device company targeting diabetes management, and as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty pharmaceutical company focused on cancer and infectious disease. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.
Listen to CEO interview: http://www.vsta.missionir.com/vsta-12-11.mp3
VSTA Contact Info
VistaGen Therapeutics Inc.
384 Oyster Point Boulevard No. 8
South San Francisco, CA 94080
Website: http://www.vistagen.com
Phone: 650-244-9990
VSTA on facebook https://www.facebook.com/VistaGen
VSTA follow their bio on twitter https://twitter.com/vistagen
Subscribe to VSTA on youtube http://www.youtube.com/user/VistaGenVSTA
Recent Developments
SEC Filings
http://www.otcmarkets.com/stock/VSTA/filings
Industry
http://finance.yahoo.com/q/in?s=VSTA+Industry
VSTA Headlines
http://finance.yahoo.com/q/h?s=VSTA+Headlines
Wednesday, April 10, 2013
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
Marketwired (Wed, Apr 10)
http://finance.yahoo.com/news/vistagen-announces-36-million-strategic-172423681.html
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
EDGAR Online (Wed, Apr 10)
http://biz.yahoo.com/e/130410/vsta8-k.html
VistaGen Announces $36 Million Strategic Financing Agreement
Marketwired (Wed, Apr 10)
Wednesday, March 13, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
EDGAR Online (Wed, Mar 13)
http://biz.yahoo.com/e/130313/vsta8-k.html
Tuesday, March 12, 2013
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire (Tue, Mar 12)
http://finance.yahoo.com/news/vistagen-therapeutics-present-enhancements-expanded-150517204.html
Monday, March 11, 2013
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire (Mon, Mar 11)
http://finance.yahoo.com/news/vistagen-therapeutics-present-cardiosafe-3d-140000662.html
Wednesday, March 6, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
EDGAR Online (Wed, Mar 6)
http://biz.yahoo.com/e/130306/vsta8-k.html
Monday, March 4, 2013
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire (Mon, Mar 4)
http://finance.yahoo.com/news/vistagen-therapeutics-enters-strategic-collaboration-140000133.html
Thursday, February 28, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
EDGAR Online (Thu, Feb 28)
http://biz.yahoo.com/e/130228/vsta8-k.html
Thursday, February 21, 2013
VISTAGEN THERAPEUTICS, INC. Financials
EDGAR Online Financials (Thu, Feb 21)
http://finance.yahoo.com/q/is?s=vsta
Thursday, February 14, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Feb 14)
http://biz.yahoo.com/e/130214/vsta10-q.html
Thursday, February 7, 2013
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire (Thu, Feb 7)
http://finance.yahoo.com/news/vistagens-collaborators-identify-definitive-precursor-150633334.html
Wednesday, January 23, 2013
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Marketwire (Wed, Jan 23)
http://finance.yahoo.com/news/vistagen-therapeutics-successfully-completes-final-133000505.html
VSTA Financial Reporting/Disclosure & Security Details
10-Q Feb 14, 2013 Dec 31, 2012 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9092413
VSTA Investor Summary: http://vsta.missionir.com/vsta/
OTCQB®
The OTCQB market tier helps investors easily identify companies that are current in their reporting obligations with the SEC or report to a U.S. banking or insurance regulator. OTCQB securities are quoted on OTC Markets Group's quotation and trading system and some may also be quoted on FINRA's BB
VSTA follows under these guidelines on the OTCQB market tier.
Investigate more @ http://www.otcmarkets.com/stock/VSTA/quote for more due diligence.
VSTA Share Structure
Shares Outstanding 20,421,787 a/o Feb 21, 2013
Float 1,101,693 a/o Feb 21, 2013
Authorized Shares 200,000,000 a/o Feb 21, 2013
Par Value 0.001
per otcmarkets.com 4/13/13
Transfer Agent(s)
Registrar and Transfer Co.
10 Commerce Drive
Cranford, NJ, 07016-1010
908-497-2300
http://www.rtco.com
Company Notes
Formerly=Excaliber Enterprises Ltd. until 6-2011
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2005
Security Notes
Capital Change=shs increased by 2 for 1 split, payable upon surrender.. Pay date=06/10/2011
VSTA bio video -Cardiac OrganDots(TM) Produced for Drug Rescue
http://www.youtube.com/watch?feature=player_embedded&v=tYWnCI8_JnQ
VSTA bio video -Stem Cell Derived Cardiomyocytes
http://www.youtube.com/watch?feature=player_embedded&v=jmvHGbx5Pyw
VSTA bio video -Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells
http://www.youtube.com/watch?feature=player_embedded&v=4XIbDj9fsXg
VSTA bio video -Technology Featured by CTV
http://www.youtube.com/watch?feature=player_embedded&v=3_NXdBA1wWQ
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, VSTA website
VSTA Business Description
VistaGen Therapeutics Inc. is biotechnology company harnessing the revolutionary power of human pluripotent stem cell technology for drug rescue and cell therapy.
VistaGen's drug rescue activities involve the combination of its human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity, despite promising efficacy data. VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube(TM), is based on directed differentiation (development) of human pluripotent stem cells into multiple types of mature cells. With heart cells produced from stem cells, VistaGen has developed CardioSafe 3D(TM), a three-dimensional biological assay (screening) system the company believes is capable of predicting the human cardiac effects, both toxic and non-toxic, of new drug candidates, long before they are tested in humans. VistaGen's immediate goal is to leverage CardioSafe 3D(TM) to generate and monetize a pipeline of small molecule drug candidates through drug rescue collaborations. VistaGen intends to expand its drug rescue capabilities by introducing LiverSafe 3D(TM), a human liver cell-based toxicity and metabolism bioassay system. In collaboration with Dr. Gordon Keller, recently named a "Top 25 Transformational Canadian" for his pioneering stem cell research and technology, VistaGen is also advancing pilot preclinical development of large market cell therapy programs, including cartilage, heart and liver repair
WATCH AWESOME 
AT THE BOTTOM OF THIS DD!
AT THE BOTTOM OF THIS DD! VSTA Pipeline and Technologies
Human Clinical Trials in a Test Tube™
$VSTA CardioSafe 3D™ is a novel bioassay system that uses mature human heart cells derived from pluripotent stem cells to screen for heart toxicity in connection with our drug rescue activities. We believe CardioSafe 3D™ is stable, reproducible and capable of generating data to allow more accurate prediction of the in vivo cardiac effects, both toxic and nontoxic, of promising new drug candidates long before they are tested in humans.
$VSTA LiverSafe 3D™
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, we are developing engineered cell lines and enhancing protocols to control the differentiation of pluripotent stem cells into normal, mature, human liver cells for use in a novel liver cell-based bioassay system for predicting liver toxicity and metabolism issues in connection with our drug rescue activities. We refer to this novel human liver cell-based bioassay system as LiverSafe 3D™. We plan to complete development of LiverSafe 3D in early-2013.
$VSTA AV-101, also known as “L-4-chlorokynurenine” and “4-Cl-KYN”, is a novel prodrug candidate that we are developing for the treatment of neuropathic pain. We are also considering AV-101 Phase 2 development opportunities relating to epilepsy, Parkinson’s disease and depression.
AV-101 is a novel, orally available prodrug that is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which is an antagonist of the N-methyl-D-aspartate (NMDA) receptors. 7-Cl-KYNA is a synthetic analogue of kynurenic acid, a naturally occurring CNS regulatory compound, and is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
In pre-clinical studies, AV-101 has demonstrated very good levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier and preferential conversion into 7-CKYNA at the site of seizures and potential neural damage in the brain and spinal cord.
AV-101 is completing Phase 1 development in the U.S. under an active Investigational New Drug (IND) application on file at the U.S. FDA that defines the initial clinical development for neuropathic pain.
We believe the safety studies completed in our AV-101 Phase 1 clinical program may also enable Phase 2 development of AV-101 for epilepsy, Parkinson’s disease and depression.
Technology: http://www.vistagen.com/technology/default.aspx
Our Human Clinical Trials in a Test Tube™ platform is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by our co-founders, renowned Canadian stem cell scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our President and Chief Scientific Officer.
Relevant Publications Relating to Licensed Technologies: http://www.vistagen.com/?page_id=322
VSTA Product Line: http://www.vistagen.com/products/Clinical-Trials-in-a-Test-Tube/default.aspx
VSTA Business Model: http://www.vistagen.com/business-model/default.aspx
VSTA VistaGen Fact Sheet: http://www.vistagen.com/Investors_Overview/default.aspx
VSTA daily chart:
VSTA Key Company Management
Shawn K. Singh CEO
H. Ralph Snodgrass President, CSO
Jerrold D. Dotson CFO
A. Franklin Rice VP, Corp. Dev.
Shawn Singh, J.D.
Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with public and private biotechnology and pharmaceutical companies,serving in numerous senior management roles. He served as Managing Principal of Cato BioVentures, a biopharmaceutical venture capital firm, as Chief Business Officer of Cato Research Ltd., a global contract research and development organization (CRO), as President of Echo Therapeutics (Nasdaq: ECTE), a medical device company targeting diabetes management, and as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), a revenue-producing specialty pharmaceutical company focused on cancer and infectious disease. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.
Listen to CEO interview: http://www.vsta.missionir.com/vsta-12-11.mp3
VSTA Contact Info
VistaGen Therapeutics Inc.
384 Oyster Point Boulevard No. 8
South San Francisco, CA 94080
Website: http://www.vistagen.com
Phone: 650-244-9990
VSTA on facebook https://www.facebook.com/VistaGen
VSTA follow their bio on twitter https://twitter.com/vistagen
Subscribe to VSTA on youtube http://www.youtube.com/user/VistaGenVSTA
Recent Developments
SEC Filings
http://www.otcmarkets.com/stock/VSTA/filings
Industry
http://finance.yahoo.com/q/in?s=VSTA+Industry
VSTA Headlines
http://finance.yahoo.com/q/h?s=VSTA+Headlines
Wednesday, April 10, 2013
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
Marketwired (Wed, Apr 10)
http://finance.yahoo.com/news/vistagen-announces-36-million-strategic-172423681.html
Quote:
SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 10, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.
Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube™ platform.
"Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated Shawn K. Singh, VistaGen's Chief Executive Officer. "Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes."
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
EDGAR Online (Wed, Apr 10)
http://biz.yahoo.com/e/130410/vsta8-k.html
VistaGen Announces $36 Million Strategic Financing Agreement
Marketwired (Wed, Apr 10)
Wednesday, March 13, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
EDGAR Online (Wed, Mar 13)
http://biz.yahoo.com/e/130313/vsta8-k.html
Tuesday, March 12, 2013
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire (Tue, Mar 12)
http://finance.yahoo.com/news/vistagen-therapeutics-present-enhancements-expanded-150517204.html
Monday, March 11, 2013
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire (Mon, Mar 11)
http://finance.yahoo.com/news/vistagen-therapeutics-present-cardiosafe-3d-140000662.html
Wednesday, March 6, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
EDGAR Online (Wed, Mar 6)
http://biz.yahoo.com/e/130306/vsta8-k.html
Monday, March 4, 2013
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire (Mon, Mar 4)
http://finance.yahoo.com/news/vistagen-therapeutics-enters-strategic-collaboration-140000133.html
Thursday, February 28, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
EDGAR Online (Thu, Feb 28)
http://biz.yahoo.com/e/130228/vsta8-k.html
Thursday, February 21, 2013
VISTAGEN THERAPEUTICS, INC. Financials
EDGAR Online Financials (Thu, Feb 21)
http://finance.yahoo.com/q/is?s=vsta
Thursday, February 14, 2013
VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Feb 14)
http://biz.yahoo.com/e/130214/vsta10-q.html
Quote:
During the first three quarters of our fiscal year ending March 31, 2013, we have continued to expand the capabilities of CardioSafe 3D and develop LiverSafe 3D. Additionally, we have continued to advance our review of prospective drug rescue candidates and have completed Phase 1 clinical development of AV-101. Our efforts during the third quarter were primarily directed to finalizing and analyzing the AV-101 Phase 1b clinical trial results and preparing final clinical study reports required under the terms of our NIH grant awards. Our executive management has been significantly focused on providing sufficient operating capital to advance our research and development objectives while meeting our continuing operational needs. To that end, we have entered into strategic debt restructuring agreements with certain long-term service providers and research and development collaborators to modify the payment requirements of our liabilities to them by significantly reducing the monthly cash payment requirements related to them, or in certain cases, to entirely restructure the liability so that it is now payable only in shares of our common stock. During the quarter ended September 30, 2012, we entered into such a strategic debt restructuring agreement with Morrison & Foerster ("M&F"), our long term outside legal counsel for intellectual property matters and certain other general corporate and finance matters. Pursuant to the M&F strategic debt restructuring agreement, we converted approximately $1.4 million of our then-existing promissory note debt to M&F into a new unsecured promissory note payable only in shares of our common stock in connection with M&F's future exercise of a warrant to purchase approximately 1.4 million shares of our common stock at $1.00 per share, provided, however, that M&F has the option to require us to repay the note in cash upon a change of control or event of default, as both are defined in the agreement. In October 2012, we entered into similar strategic debt restructuring agreements with Cato Research Ltd. ("CRL"), our CRO collaborator for preclinical and Phase 1 clinical development of AV-101, and University Health Network ("UHN"), our long-term stem cell research and development collaborator in Canada, in which we converted approximately $1.0 million of existing accounts payable debt owed to CRL and approximately $0.55 million of existing accounts payable debt owed to UHN into new notes payable only in shares of our common stock in connection with future warrant exercises by CRL and UHN to purchase approximately 1.0 million and 0.55 million shares of our common stock, respectively, at $1.00 per share. Additionally, we have reduced the current monthly unsecured promissory note payment requirements with respect to existing debt of $1.0 million owed to M&F and $0.3 million owed to Cato Holding Company. Further, we have entered into an agreement with our largest institutional investor, Platinum Long Term Growth VII, LLC ("Platinum"), pursuant to which we expect to receive an aggregate of $3.25 million in cash proceeds, $2.25 million of which we have already received, from the issuance of senior secured convertible promissory notes and related warrants to purchase 3.25 million shares of our common stock. Subject to certain adjustments, these notes are convertible into shares of our common stock at a conversion price of $0.50 per share and the warrants are exercisable at an exercise price of $1.50 per share. Additionally, we modified Platinum's exchange rights with respect to the shares of our Series A preferred stock that it holds. These transactions are described in greater detail in Note 7, Convertible Promissory Notes and Other Notes Payable and Note 9, Capital Stock, in the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The accounting for these transactions has resulted in the recognition of non-cash losses due to certain of the modifications (loss on early extinguishment of debt) and non-cash interest expense in the financial statements for the quarter and fiscal year-to-date. These transactions, which will potentially require or permit the issuance of shares of our common stock at various points in the future, may be substantially dilutive to our existing stockholders.
Thursday, February 7, 2013
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire (Thu, Feb 7)
http://finance.yahoo.com/news/vistagens-collaborators-identify-definitive-precursor-150633334.html
Wednesday, January 23, 2013
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Marketwire (Wed, Jan 23)
http://finance.yahoo.com/news/vistagen-therapeutics-successfully-completes-final-133000505.html
VSTA Financial Reporting/Disclosure & Security Details
10-Q Feb 14, 2013 Dec 31, 2012 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9092413
VSTA Investor Summary: http://vsta.missionir.com/vsta/
OTCQB®
The OTCQB market tier helps investors easily identify companies that are current in their reporting obligations with the SEC or report to a U.S. banking or insurance regulator. OTCQB securities are quoted on OTC Markets Group's quotation and trading system and some may also be quoted on FINRA's BB
VSTA follows under these guidelines on the OTCQB market tier.
Investigate more @ http://www.otcmarkets.com/stock/VSTA/quote for more due diligence.
VSTA Share Structure
Shares Outstanding 20,421,787 a/o Feb 21, 2013
Float 1,101,693 a/o Feb 21, 2013
Authorized Shares 200,000,000 a/o Feb 21, 2013
Par Value 0.001
per otcmarkets.com 4/13/13
Transfer Agent(s)
Registrar and Transfer Co.
10 Commerce Drive
Cranford, NJ, 07016-1010
908-497-2300
http://www.rtco.com
Company Notes
Formerly=Excaliber Enterprises Ltd. until 6-2011
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2005
Security Notes
Capital Change=shs increased by 2 for 1 split, payable upon surrender.. Pay date=06/10/2011
VSTA bio video -Stem Cell Derived Cardiomyocytes
VSTA bio video -Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells
VSTA bio video -Technology Featured by CTV
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, VSTA website
No comments:
Post a Comment